Lukasz Bolkun
Overview
Explore the profile of Lukasz Bolkun including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
275
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pomykala K, Drozd-Sokolowska J, Maczewska J, Kacprzyk P, Bolkun L, Styczynski G, et al.
Kardiol Pol
. 2024 Oct;
83(1):83-84.
PMID: 39377628
No abstract available.
2.
Charlinski G, Szudy-Szczyrek A, Podgajna M, Mielnik M, Kopinska A, Tyczynska A, et al.
Adv Clin Exp Med
. 2024 Aug;
PMID: 39206811
Background: Non-secretory multiple myeloma (NSMM) accounts for approx. 2-3% of multiple myeloma (MM) cases. Due to the rare occurrence and ineligibility of patients with NSMM to participate in clinical trials,...
3.
Karasek M, Armatys A, Skarupski M, Bolkun L, Budziszewska K, Drozd-Sokolowska J, et al.
Front Oncol
. 2024 Jun;
14:1395992.
PMID: 38835383
Introduction: Mixed-phenotype acute leukemia (MPAL) is a rare disease with poor prognosis. So far, no standard approach has been established as the "know-how" of MPAL is based only on retrospective...
4.
Sobieralski P, Bieniaszewska M, Bolkun L, Sacha T, Muzalewska-Wolska M, Homenda W, et al.
Adv Clin Exp Med
. 2024 Apr;
34(1):25-32.
PMID: 38683044
Background: The treatment of patients with polycythemia vera (PV) and essential thrombocythemia (ET) is conducted according to well-defined risk stratification systems. We hypothesized that adherence to the guidelines, namely the...
5.
Bolkun L, Starosz A, Kretowska-Grunwald A, Wasiluk T, Walewska A, Wierzbowska A, et al.
Cancers (Basel)
. 2024 Jan;
16(2).
PMID: 38275902
Despite substantial progress in the diagnostic and therapeutic procedures, acute myeloid leukaemia (AML) still constitutes a significant problem for patients suffering from its relapses. A comprehensive knowledge of the disease's...
6.
Bolkun L, Pienkowski T, Sieminska J, Godzien J, Pietrowska K, Kloczko J, et al.
Sci Rep
. 2023 Dec;
13(1):21809.
PMID: 38071228
The heterogeneity of acute myeloid leukemia (AML), a complex hematological malignancy, is caused by mutations in myeloid cells affecting their differentiation and proliferation. Thus, various cytogenetic alterations in AML cells...
7.
Sosnia O, Pruszczyk K, Danecki M, Wasik-Szczepanek E, Tryc-Szponder J, Iskierka-Jazdzewska E, et al.
Leuk Lymphoma
. 2023 Nov;
65(2):175-186.
PMID: 37921067
Richter transformation (RT) is defined as developing an aggressive lymphoma in 2-10% of patients suffering from chronic lymphocytic leukemia (CLL). So far, no complex analysis of RT demographics and treatment...
8.
Bolkun L, Tynecka M, Walewska A, Bernatowicz M, Piszcz J, Cichocka E, et al.
Cancers (Basel)
. 2023 Sep;
15(18).
PMID: 37760457
The development of novel drugs with different mechanisms of action has dramatically changed the treatment landscape of AML patients in recent years. Considering a significant dysregulation of the immune system,...
9.
Charlinski G, Grzasko N, Bolkun L, Sawicki W, Paczkowska E, Druzd-Sitek A, et al.
J Oncol Pharm Pract
. 2023 Sep;
30(7):1144-1151.
PMID: 37728209
Introduction: Therapeutic adherence (TA) is one of the most important factors influencing the effectiveness of treatment. Oral anti-cancer drugs are increasingly used to treat malignancy including multiple myeloma (MM). Our...
10.
Sobon A, Drozd-Sokolowska J, Paszkiewicz-Kozik E, Poplawska L, Morawska M, Tryc-Szponder J, et al.
Ann Hematol
. 2023 Jul;
102(8):2119-2126.
PMID: 37392368
The results of the MURANO trial showed encouraging progression-free survival (PFS) and overall survival (OS) in relapsed/refractory chronic lymphocytic leukemia (RR-CLL) patients treated with venetoclax-rituximab (VEN-R). A retrospective analysis was...